Establishment Labs (NASDAQ:ESTA) Receives Buy Rating from BTIG Research

Establishment Labs (NASDAQ:ESTA)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research note issued on Tuesday, Benzinga reports. They currently have a $103.00 target price on the stock. BTIG Research’s price target would indicate a potential upside of 48.56% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Mizuho increased their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Needham & Company LLC lifted their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.25.

Establishment Labs Stock Performance

ESTA stock opened at $69.33 on Tuesday. The firm has a market cap of $2.07 billion, a PE ratio of -52.92 and a beta of 1.07. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs has a 12-month low of $36.53 and a 12-month high of $97.59. The business has a 50 day moving average of $84.67 and a 200-day moving average of $74.92.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter in the previous year, the business earned ($0.57) EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. As a group, sell-side analysts expect that Establishment Labs will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its stake in Establishment Labs by 8,625.7% in the second quarter. California State Teachers Retirement System now owns 1,930,124 shares of the company’s stock worth $165,624,000 after purchasing an additional 1,908,004 shares during the last quarter. BlackRock Inc. bought a new position in shares of Establishment Labs during the second quarter valued at approximately $135,752,000. William Blair Investment Management LLC purchased a new stake in shares of Establishment Labs in the second quarter worth approximately $61,273,000. Bank of America Corp DE purchased a new stake in shares of Establishment Labs in the second quarter worth approximately $52,176,000. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Establishment Labs during the 2nd quarter worth approximately $48,134,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.